Precision medicine

How is fierce ambition translated into the reality of building two world-class personalized healthcare institutes?

C-reactive protein levels and genetic variations are linked to increased risk of a second ischemic stroke

In patients with early-stage breast cancer, the neutrophil-to-lymphocyte ratio may indicate future risk of recurrence

Kinetic models offer a single test to predicts patients' likelihood of drug side effects.

Understanding the genetic basis of recurrent IVF failure may help counsel couples.

What does analysis of the last five years of literature on companion diagnostics tell us about the priorities of the field, and the contributors to it?

Keith Miller is Director and co-founder of CADQAS (Cancer Diagnostic Quality Assurance Services), a not-for-profit community interest company hosted by Poundbury Cancer Institute (PCI).

Christopher Hudson is Director of Tissue Diagnostics UK and Ireland at Roche, the multinational life sciences company that supports the Poundbury Cancer Institute through funding and research collaboration.

Poundbury Cancer Institute aims to put pathology at the forefront of cancer research, and bring industry, national healthcare service and quality assurance together to expand the use of companion diagnostics and important biological markers.

At the Poundbury Cancer Center, pathology, business and quality assurance are uniting to create a cutting-edge home for companion diagnostics.